We further confirmed the up-regulation of FTO in the group of DNBC (ER−/PR−/Her2+) and late stages (GRADE II and III) three clinical stages of breast cancer (Fig. 1c), suggesting that FTO may play a predominant role in mediating m6A modification in breast cancer. The gene discussed is ERBB2; the disease is breast cancer.